12

News

Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies

Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies Iconovo has entered into a feasibility…
Read more

Iconovo Accelerator Program

On June 1st, 2023 Iconovo launched its Iconovo Accelerator to facilitate the opportunities for the company’s customers to obtain EU funding for the development…
Read more

ICOne Nasal at European Synchrotron Radiation Facility

Read more

PRODUCTS

Four differentiated technical platforms, available for customization

Iconovo offers the development of inhalation products — inhaler devices and dry powder formulation — and assists in clinical trials and registration. We also offer proprietary generic drugs. The inhalation platforms are primarily intended for asthma and chronic obstructive pulmonary disease (COPD) treatment.

Learn more…

SERVICES

Seeking a fast and safe way to reach the market?

We work with international generic drug companies and pharmaceutical companies that lack the expertise, resources and/or time to develop the product themselves. Our development time is shorter and consequently more cost-effective since we have ready-to-use platforms with inhalation products that can be modified for a specific drug.

Learn more…

CAPABILITIES

We develop new ideas in inhalation

Iconovos highly skilled employees offers a comprehensive service package including device design, formulation development, analytical testing and documentation. Iconovo has build its own state-of-the-art laboratories for analysis, development and characterization of powder formulations.
Learn more…

Read more about our customer collaborations

Want to know when we got news on our platforms? Sign up for our press releases now!

SIGN UP